

(51) International Patent Classification:
C07D 265/30 (2006.01)(21) International Application Number:
PCT/US2023/015461(22) International Filing Date:
17 March 2023 (17.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/321,423 18 March 2022 (18.03.2022) US(71) Applicant: SUPERNUS PHARMACEUTICALS, INC.
[US/US]; 9715 Key West Ave., Rockville, Maryland 20850 (US).

(72) Inventors: SUN, Yanjun; 14 Greyhound Court, Kendall Park, New Jersey 08824 (US). NALLAGANCHU, Bhaskara Rao; 99 Nostrand Road, Hillsborough, New Jersey 08844 (US). OLSON, Gary L.; 1505 Coles Avenue, Mountainside, New Jersey 07092 (US).

(74) Agent: MAEBIUS, Stephen B. et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).




Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES

(57) Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the following chemical structure: (IIf)

FIG. 1



Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*